WallStreetZenWallStreetZen

NASDAQ: VERV
Verve Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VERV

Based on 4 analysts offering 12 month price targets for Verve Therapeutics Inc

Min Forecast
$15.00+213.81%
Avg Forecast
$25.75+438.7%
Max Forecast
$39.00+715.9%

Should I buy or sell VERV stock?

Based on 4 analysts offering ratings for Verve Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VERV's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VERV as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their VERV stock forecasts and price targets.

VERV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-15Find Out Why
lockedlocked$00.00+00.00%2025-04-15
lockedlocked$00.00+00.00%2025-04-14
lockedlocked$00.00+00.00%2025-03-04

1 of 1

Forecast return on equity

Is VERV forecast to generate an efficient return?

Company
-43.55%
Industry
153.19%
Market
81.87%
VERV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERV forecast to generate an efficient return on assets?

Company
-33.19%
Industry
36.07%
VERV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERV earnings per share forecast

What is VERV's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.73
Avg 2 year Forecast
-$2.80
Avg 3 year Forecast
-$2.70

VERV revenue forecast

What is VERV's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$29.7M-8.02%
Avg 2 year Forecast
$18.5M-42.94%
Avg 3 year Forecast
$18.5M-42.94%
VERV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VERV revenue growth forecast

How is VERV forecast to perform vs Biotechnology companies and vs the US market?

Company
-20.16%
Industry
65.48%
Market
10.37%
VERV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VERV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VERV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERV$4.78$25.75+438.70%Strong Buy
DNA$7.34N/AN/A
MNMD$5.66$26.80+373.50%Buy
TRML$16.76$45.20+169.69%Buy
PRTC$16.74N/AN/A
View Top Biotech Stocks

Verve Therapeutics Stock Forecast FAQ

Is Verve Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: VERV) stock is to Strong Buy VERV stock.

Out of 4 analysts, 2 (50%) are recommending VERV as a Strong Buy, 2 (50%) are recommending VERV as a Buy, 0 (0%) are recommending VERV as a Hold, 0 (0%) are recommending VERV as a Sell, and 0 (0%) are recommending VERV as a Strong Sell.

If you're new to stock investing, here's how to buy Verve Therapeutics stock.

What is VERV's earnings growth forecast for 2025-2027?

(NASDAQ: VERV) Verve Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Verve Therapeutics's earnings in 2025 is -$198,709,000.On average, 5 Wall Street analysts forecast VERV's earnings for 2025 to be -$242,590,038, with the lowest VERV earnings forecast at -$265,499,346, and the highest VERV earnings forecast at -$211,333,928. On average, 3 Wall Street analysts forecast VERV's earnings for 2026 to be -$248,628,150, with the lowest VERV earnings forecast at -$269,051,177, and the highest VERV earnings forecast at -$237,084,701.

In 2027, VERV is forecast to generate -$239,748,574 in earnings, with the lowest earnings forecast at -$301,905,611 and the highest earnings forecast at -$208,670,055.

What is VERV's revenue growth forecast for 2025-2027?

(NASDAQ: VERV) Verve Therapeutics's forecast annual revenue growth rate of -20.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Verve Therapeutics's revenue in 2025 is $32,332,000.On average, 3 Wall Street analysts forecast VERV's revenue for 2025 to be $2,640,786,140, with the lowest VERV revenue forecast at $1,092,187,946, and the highest VERV revenue forecast at $4,645,794,582. On average, 2 Wall Street analysts forecast VERV's revenue for 2026 to be $1,638,281,920, with the lowest VERV revenue forecast at $1,092,187,946, and the highest VERV revenue forecast at $2,184,375,893.

In 2027, VERV is forecast to generate $1,638,281,920 in revenue, with the lowest revenue forecast at $1,092,187,946 and the highest revenue forecast at $2,184,375,893.

What is VERV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VERV) forecast ROA is -33.19%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is VERV's Price Target?

According to 4 Wall Street analysts that have issued a 1 year VERV price target, the average VERV price target is $25.75, with the highest VERV stock price forecast at $39.00 and the lowest VERV stock price forecast at $15.00.

On average, Wall Street analysts predict that Verve Therapeutics's share price could reach $25.75 by Apr 15, 2026. The average Verve Therapeutics stock price prediction forecasts a potential upside of 438.7% from the current VERV share price of $4.78.

What is VERV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VERV) Verve Therapeutics's current Earnings Per Share (EPS) is -$2.35. On average, analysts forecast that VERV's EPS will be -$2.73 for 2025, with the lowest EPS forecast at -$2.99, and the highest EPS forecast at -$2.38. On average, analysts forecast that VERV's EPS will be -$2.80 for 2026, with the lowest EPS forecast at -$3.03, and the highest EPS forecast at -$2.67. In 2027, VERV's EPS is forecast to hit -$2.70 (min: -$3.40, max: -$2.35).

What is VERV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VERV) forecast ROE is -43.55%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.